Prostate Cancer: ERLEADA (apalutamide) Delayed Metastases While Not Reducing Quality of Life Interview with:

Dr. Fred Saad, MD FRCS Full Professor and Chief of Urologic Oncology, CHUM; Medical Director of Interdisciplinary Urologic Oncology Group, CHUM; Department of Surgery/Faculty of Medicine; Institut du cancer de Montréal/CRCHUM

Dr. Saad

Dr. Fred Saad, MD FRCS
Professor and Chief of Urology
Director of GU Oncology
Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center (CHUM)
Director, Prostate Cancer Research , Montreal Cancer Institute What is the background for this study? What are the main findings?

Response: Patient Reported Outcomes (PRO) data from the Phase 3 SPARTAN study showed adding ERLEADA (apalutamide) to androgen deprivation therapy (ADT) for patients with nmCRPC who were asymptomatic and well, did not worsen or cause detriment to HRQoL when compared to the placebo.The percent of patients who felt “quite a bit” or “very much” bothered was low (<2–6 percent of patients in the apalutamide group and 0–6 percent of those in the placebo group), suggesting that ERLEADA treatment was generally well-tolerated. This outcome, coupled with the efficacy results seen in SPARTAN, suggest that apalutamide can be given to patients at risk of metastasis without worry about compounded side effects or negative HRQoL.. What should readers take away from your report?

Response: This is the first report on HRQoL associated with a novel treatment that has been shown to significantly delay metastases and prolong metastasis-free and symptomatic progression-free survival in this patient population. Patient reported outcomes data are gaining importance as healthcare systems place greater emphasis on the patient’s experience with the treatment. What recommendations do you have for future research as a result of this work?

Response: As we move prostate cancer care from acute to chronic in nature, Patient Reported Outcomes data should become standard across treatments. Future clinical trials in prostate cancer should include similar outcomes measures so we can best compare and contrast overall treatment success.

Citation: AUA 2018 

For easy reference, here is the abstract:

Patient Reported Outcomes (PROs) in SPARTAN, a Phase 3, Double-Blind, Randomized Study of Apalutamide(APA) Plus Androgen Deprivation Therapy (ADT) vs Placebo Plus ADT in Men With Nonmetastatic Castration-Resistant Prostate Cancer 

March 2018
Volume 17, Issue 2, Pages e1070–e1071

[wysija_form id=”3″] 

The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.